# Assessing and Managing Chronic Non-Cancer Pain



# **Conflict of Interest Disclosure and Funding Support**

This material is produced through a financial contribution by Health Canada's Substance Use and Addiction Program. The views expressed herein do not necessarily represent the views of Health Canada

#### **Content Creation:**

CADTH; Clinical Expert Input provided by Dr. Richard Dumais

#### **Disclosures**

- CADTH is an independent, not-for-profit organization funded by funded by contributions from the Canadian federal, provincial, and territorial ministries of health, with the exception of Quebec.
- CADTH receives application fees from the pharmaceutical industry for:
- CADTH Pharmaceutical Reviews: Common Drug Review, pan-Canadian Oncology Drug Review, Interim Plasma Protein Product Review
- CADTH Scientific Advice

#### **Commercial interests:**

None



# **Collaborators**

# The following organizations supported the development of this educational module:

- New Brunswick Department of Health
- New Brunswick Medical Society
- Choosing Wisely New Brunswick
- CADTH







Choisir avec soin Nouveau-Brunswick



# **Learning Objectives**

- 1. Describe the central features, classification of, and current issues related to chronic non-cancer pain (CNCP) in Canada
- 2. Recognize recommended approaches to the management of CNCP, including assessment (and recognition of the dominant pain mechanism) and treatment options
- 3. Identify and apply contemporary evidence-based guidance and tools for managing patients with CNCP
- 4. Discuss and implement strategies for managing complex patients with CNCP using a case-based approach





"CNCP includes any painful condition that persists for at least three months and is not associated with malignant disease"

**Chronic Pain in Canada** 

#### 7.63 Million Canadians

#### **Risk factors**

- Drug users
- Low SES
- Indigenous Peoples
- Ethnic minorities
- Women
- Individuals who have experienced trauma



Health Canada. Canadian Pain Task Force Report: September 2020. Published November 6, 2020.



# **Impact of Chronic Pain**









Health Canada. Canadian Pain Task Force Report: September 2020. Published November 6, 2020.

# Canadian Pain Task Force (CPTF)

- Established by Health Canada (March 2019) to advise on evidence and best practices for preventing and managing chronic pain
- Mandated to:
  - o assess how chronic pain is currently addressed in Canada
  - conduct national consultations and evidence reviews to identify best practices, areas for improvement, and elements of an improved approach to chronic pain
- Created to provide recommendations on priority actions to ensure recognition and support of people with pain, and that pain is understood, prevented, and effectively treated across Canada

Health Canada. Canadian Pain Task Force. December 17, 2020.



# **CPTF Key Findings 2020**

- Issues regarding access to timely and patient-centred pain care
- Need for better awareness, education, and specialized training for pain; improved pain research and related infrastructure; and standardization in monitoring population health and health system quality related to chronic pain
- Looking ahead, care for Indigenous Peoples must acknowledge negative experiences (including bias and racism) and recognize traditional, traumainformed, and violence-informed approaches



Health Canada. Canadian Pain Task Force Report: September 2020.



# **Prioritizing Chronic Pain in Primary Care**

In spring 2020, Chronic Pain was added as a priority to the Assessment Objectives for Certification in Family Medicine published by the College of Family Physicians of Canada, outlining essential skills and competencies expected at the end of training.

Chronic pain was also specifically highlighted as a priority topic for rural and remote family medicine



College of Family Physicians of Canada. Assessment Objectives for Certification in Family Medicine, Second Edition. 2020.



**Challenges Facing Individuals Living With Chronic Pain** 

Both COVID-19 and record numbers of opioid-related deaths have had a great impact on the lives of individuals living with chronic pain




Health Canada. Canadian Pain Task Force Report: September 2020. Published November 6, 2020.



# **Chronic Pain and COVID-19**

- Individuals with CNCP may be at increased risk for COVID-19 and mental health concerns
- CNCP (and treatments for CNCP) may increase immunosuppression and infection risk
- Mental health concerns exacerbated by the pandemic may impact quality of life, experience of pain, and safety
- Recent simulations by the Public Health
  Agency of Canada suggest potential increases
  in opioid-related harms and death related to
  the pandemic



Government of Canada. Modelling opioid overdose deaths during the COVID-19 outbreak. Published November 26, 2020.



# **New Brunswick**

#### In 2020 (January to September):

- Opioid-related harms remain a pressing concern
- 94 EMS responses to suspected overdoses
- 317 naloxone administrations to suspect opioid overdose patients (125 responded)
- 76 hospitalizations
- 21 deaths

Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioids and stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada; March 2021.

Surveillance of apparent opioid overdoses, 2020 Q3&4, Public Health New Brunswick, May 2021.



# In the News...

#### As Canada's overdose deaths soar, the safe-supply debate enters a new and urgent phase

Fentanyl-related deaths have hit new heights in the pandemic, putting pressure on programs to protect vulnerable people from toxic street drugs – and renewing questions about why not all provinces have them

The Globe and Mail, February 18, 2021

British Columbia

# 2020 was B.C.'s deadliest year ever for drug overdoses, coroner says

1,716 people died due to illicit drug use last year, equating to 4.7 deaths a day — a 74% increase over 2019

CBC News, January 30, 2021

Toronto

# Paramedics attend a record 40 suspected opioid overdose calls, 3 deaths in 24 hours

Toronto saw record number of overdose deaths in December 2020 alone, public health unit says

CBC News, February 11, 2021

HEALTH | News

Pandemic aggravates opioid crisis as overdoses rise and services fall out of reach

The Canadian Press Str

Published Sunday, November 15, 2020 7:07AM EST

CTV News, November 15, 2020




# Increase in Opioid-Related Harms — Why?

- Changes in illegal drug supply
- Reduced access to services and supports (particularly in-person)
- Increased use of substances to cope with stress

# How to support chronic pain patients during the pandemic?

Push to minimize in-person visits, leverage virtual care and online supports, emphasize harm reduction



Health Canada. Modelling opioid overdose deaths during the COVID-19 outbreak. November 26, 2020.




# **New Brunswick Prescription Monitoring**

#### **Local Tools**

- Electronic access to full medication summary including monitored drug prescriptions (e.g., opioids, benzodiazepines, stimulants)
- Enables early identification of New Brunswickers at risk of monitored drug-related harm and promotes optimal prescribing and use of monitored drugs for those who need them
- Key data on monitored drugs can alert to issues (e.g., double-doctoring, high doses, risky drug combinations)







# **Classifying Pain**

- Not all pain is the same
- There are many approaches to classifying pain
- Identifying the dominant pain mechanism is important during assessment to support decisionmaking about optimal tailored management of CNCP
- Lack of consensus about how to classify and discriminate between pain mechanisms

- Overlap between categories of pain (multiple mechanisms may be present to varying degrees)
- Diversity of terminology

Shraim MA et al. Methods to discriminate between mechanism-based categories of pain experienced in the musculoskeletal system: a systematic review. Pain. 2021;162(4):1007-1037.

Shraim MA et al. Systematic Review and Synthesis of Mechanism-based Classification Systems for Pain Experienced in the Musculoskeletal System. Clin J Pain. 2020;36(10):793-812



# **Mechanism-Based Classification**

- There are numerous tools used in the classification of pain (e.g., clinical examination, quantitative testing, imaging, diagnostic and laboratory testing, and questionnaires)
- International Association for the Study of Pain (IASP) ICD-11 pain mechanism categories (nociceptive, neuropathic, nociplastic)
- Three multicomponent systems (i.e., Smart, Schafer, and Kolski) for discriminating pain mechanisms and identifying the dominant mechanism
- Three category—specific systems (e.g., Berlin for inflammatory pain, RAPIDH for radicular pain, neuropathic pain special interest group [NeuPSIG] for neuropathic pain)

Shraim MA et al. Methods to discriminate between mechanism-based categories of pain experienced in the musculoskeletal system: a systematic review. Pain. 2021;162(4):1007-1037. Shraim MA et al. Systematic Review and Synthesis of Mechanism-based Classification Systems for Pain Experienced in the Musculoskeletal System. Clin J Pain. 2020;36(10):793-812.





# Pain Mechanism Classification System (PMCS)

Smart et al. multicomponent system

**Nociceptive** 

(Peripheral)
Neuropathic

Nociplastic (Central Sensitization)

Smart KM, Blake C, Staines A, Doody C. The Discriminative validity of "nociceptive," "peripheral neuropathic," and "central sensitization" as mechanisms-based classifications of musculoskeletal pain. Clin J Pain. 2011;27(8):655-663. doi:10.1097/AJP.0b013e318215f16a



# **Nociceptive**

Pain associated with tissue injury or damage and related inflammation.
Affects joints, ligaments, muscles

**Associated Conditions:** Osteoarthritis, tendinopathies, repetitive strain injuries, fractures, sprains, rheumatoid arthritis, ankylosing spondylitis





# **Nociceptive**



# **Symptoms and Signs**

- Pain localized to the area of injury or dysfunction (somatic referral)
- Intermittent and sharp pain with movement or mechanical provocation
- Constant dull ache or throbbing at rest
- Associated with dysesthesias (e.g., crawling sensation)
- Clear, proportionate relationship with aggravating/easing factors

Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 3 of 3: symptoms and signs of nociceptive pain in patients with low back (± leg) pain. Man Ther. 2012;17(4):352-357. doi:10.1016/j.math.2012.03.002



# **Nociceptive**



# **Symptoms and Signs**

#### Absence of:

- Night pain / disturbed sleep
- Antalgic (i.e., pain relieving) postures / movement patterns
- Pain described as burning, shooting, sharp or "electric shock like"

Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 3 of 3: symptoms and signs of nociceptive pain in patients with low back (± leg) pain. Man Ther. 2012;17(4):352-357. doi:10.1016/j.math.2012.03.002



# (Peripheral) Neuropathic

Nerve generated pain distal to the dorsal root ganglion. Associated with injury or disease of nerve tissue

**Associated conditions:** Fibromyalgia, trigeminal neuralgia, diabetic neuropathy





# (Peripheral) Neuropathic



# **Symptoms and Signs**

- Pain referred in a dermatomal or cutaneous distribution
- History of nerve injury, pathology, or mechanical compromise
- Pain/symptom provocation with mechanical/ movement tests (e.g., active/passive, neurodynamic) that move/load/compress neural tissue


Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 2 of 3: symptoms and signs of peripheral neuropathic pain in patients with low back (± leg) pain. Man Ther. 2012;17(4):345-351. doi:10.1016/j.math.2012.03.003



# **DN4 Questionnaire**

- Screening tool that assesses sensory descriptors and signs associated with neuropathic pain
- Scores ≥ 4 suggest likely neuropathic pain

Bouhassira, Didier, et al. "Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)." pain 114.1-2 (2005): 29-36.





# **Nociplastic (Central Sensitization)**

Pain due to altered nociception despite no clear evidence of tissue damage

**Associated Conditions:** Low back pain, whiplash, migraine, restless leg syndrome, fibromyalgia





# **Nociplastic (Central Sensitization)**



# **Symptoms and Signs**

- Diffuse/non-anatomic areas of pain/tenderness on palpation
- Disproportionate pattern of pain provocation in response to multiple/nonspecific aggravating/easing factors
- Pain disproportionate to the nature and extent of injury/pathology
- Strong association with maladaptive psychosocial factors (e.g., negative motions, poor self-efficacy, maladaptive beliefs, and pain behaviours, altered family/work/social life, and medical conflict)

Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with low back (± leg) pain. Man Ther. 2012;17(4):336-344. doi:10.1016/j.math.2012.03.013





# Quiz

**Q:** What are some population groups that are at increased risk of CNCP in Canada?






# Quiz

**A:** Some of the population groups that are at increased risk of CNCP in Canada are:

- Drug users
- Low SES
- Indigenous Peoples
- Ethnic minorities
- Women
- Individuals who have experienced trauma








# 2017 Canadian CNCP Guidelines

- The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain
- Intended as a basis for decisions around using opioids and managing CNCP
- Recommendations not intended as absolute and should not replace clinical judgment



Busse, Jason, et al. "The 2017 Canadian guideline for opioids for chronic non-cancer pain." Hamilton, ON (2017).



# **Key Recommendations**

- Optimization of nonopioid pharmacotherapy and nonpharmacologic therapy<sup>a</sup>
- Opioid trial only after optimization of nonopioid and non-drug measures<sup>b</sup>
- Avoidance of opioid therapy in those with a history of or active substance use disorder<sup>a</sup>, or active mental illness<sup>b</sup>
- When initiating opioids restrict dose to less than 90 mg morphine equivalents daily (MED)<sup>a</sup> and less than 50 mg MED maximum prescribed dose<sup>b</sup>
- Gradual dose taper<sup>b</sup> and multidisciplinary support<sup>a</sup> for those receiving high-dose opioid therapy

Busse, Jason W., et al. "Guideline for opioid therapy and chronic noncancer pain." Cmaj 189.18 (2017): E659-E666.




<sup>&</sup>lt;sup>a</sup> Strong Recommendation

<sup>&</sup>lt;sup>b</sup> Weak Recommendation

# **Tools to Support Implementation**

Centre for Effective Practice (CEP)



Chronic Non-Cancer Pain (Clinical Products). Centre for Effective Practice. 2018.



### **Centre for Effective Practice**

- Designed to help primary care providers manage patients with CNCP
- Tool reflects 2017 Canadian Guideline recommendations
- Covers:
  - Baseline and ongoing assessment
  - Non-pharmacological therapy
  - Non-opioid medications
  - Opioid medications
  - Intervention management and referral



Management of Chronic Non-Cancer Pain. Centre for Effective Practice. 2020.



# **General Approach to Assessment and Management**

Assess

Create a management plan

Initiate, adapt, and evaluate treatment(s)

Refer, as appropriate

- Baseline and ongoing assessment
- Management plan
  - Non-pharmacological therapies
  - Non-opioid medications
  - Opioid medications

 Intervention management or referral (to specialist or multidisciplinary care)



Management of Chronic Non-Cancer Pain. Centre for Effective Practice. 2020



# **Baseline and Ongoing Assessment**


- Pain condition and physical examination
- Functional and social history
- Mental health assessment
- Substance use history and opioid risk assessment
- Yellow flags




Management of Chronic Non-Cancer Pain. Centre for Effective Practice. 2020



# **Brief Pain Inventory**







# **Treatment Options**

### **Pharmacological**

- Opioid
- Non-Opioid

### Non-Pharmacological

- Physical
- Psychological
- Preventive



CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Published online 2020. CADTH. Non-Opioid Options for Managing Adult Chronic Pain. Published online 2020. Centre for Effective Practice (CEP) Providers | Chronic Non-Cancer Pain.



# **Access and Availability**

- Generally, non-drug treatments are less accessible and available, particularly in rural, remote, and non-specialty settings
- Access limited by long wait times (e.g., for pain clinics; multidisciplinary care), lack of public funding, lack of coordination and continuity of care, and referrals
- These are common trends observed in other industrialized countries irrespective of the health care system
- Lack of utilization of guidance to inform non-pharmacological treatment
- Need for guidance (including for tailored treatment) expressed by practitioners

# CADTH Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan

CADTH. Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan. 2018.



# Non-Drug Ways to Manage Chronic Pain

**CADTH** (chronicpain)







**Psychological** 


**Preventive** 



# Non-Opioid and Non-Drug Strategies







CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Published online 2020. CADTH. Non-Opioid Options for Managing Adult Chronic Pain. Published online 2020.



### **Clinician Tool**

### **Chronic Pain Prescription Pad to Support Self-Management**






CADTH. Thinking Outside the Medicine Cabinet - Non-Drug Ways to Manage Chronic Pain. Published online 2020.



### **RxFiles Pain Mini-Book**

- CNCP Treatment Colour Chart tool to help individualize and optimize therapy for individuals with CNCP
- Prescribing Opioids Safety chart
- Opioid Tapering chart and template



Pain Management & Opioids - RxFiles





### **Patient Profile**

Age: 75 years Sex: Female



Experiencing side effects from current medication including weight gain, sleep disturbances



Diagnosed with chronic fibromyalgia 3 years ago



Recent complaints of persistent pain and dizziness limiting ability to conduct activities of daily living



### **Overview**



### **Medical Conditions**


- Chronic fibromyalgia
- Obesity
- Hypertension
- Type 2 diabetes (well managed)
- Insomnia

### **Select Labs / Vitals**

- A1C 7.2%
- CrCl 68 mL/min
- BP 124/79
- BMI 32



### **Overview**




#### **Functional Satus**

- Lives alone
- Recently stopped volunteering and reduced social activity (weekly walks)
- Pain 8/10 (VAS) household chores;
   5/10 at rest
- BPI (70/100)
- Shifting musculoskeletal pains in legs, back, and arms



### **Overview**



### Dominant pain mechanism:

Nociplastic (central sensitization)



### **Additional Information**

- Patient describes horrible pain all day, burning sensation and a feeling that she is on fire. Increased sensitivity to cold air and water
- Tired all the time sometimes in bed for 1 or 2 days consecutively if she does too much
- Difficulty sleeping due to pain resulting in daytime drowsiness, needs daily nap to complete ADLs

- Persistent severe pain and functional limitations despite drug treatment, particularly with repeated movements
- Bothered by side effects (dizziness) of current medications
- Increased demands to care for spouse
- Has not been offered nonpharmacological strategies



### **Dominant Pain Mechanism**

# **Nociplastic (Central Sensitization) Symptoms and Signs**

- Diffuse/non-anatomic areas of pain/tenderness on palpation
- Disproportionate pattern of pain provocation in response to multiple/nonspecific aggravating/easing factors
- Pain disproportionate to the nature and extent of injury/pathology
- Strong association with maladaptive psychosocial factors (e.g., negative motions, poor self-efficacy, maladaptive beliefs, and pain behaviours, altered family/work/social life, and medical conflict)

Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with low back (± leg) pain. Man Ther. 2012;17(4):336-344. doi:10.1016/j.math.2012.03.013



# **EULAR Fibromyalgia Recommendations**

- Focus first on non-pharmacological modalities (strong recommendation for exercise, weak for other modalities)
- Consider psychological therapies (i.e., cognitive behavioural therapy) for those with mood disorder or unhelpful coping strategies (weak recommendation)
- Pharmacological treatment should be considered for those with severe pain (duloxetine, pregabalin, tramadol) or sleep disturbance (amitriptyline, cyclobenzaprine, pregabalin) (weak recommendation)
- Multimodal rehabilitation programs should be considered for those with severe disability (weak recommendation)

Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724



# **Current Therapy**

**Non-opioid drug treatments:** 

Pregabalin 150 mg BID

Metformin 1,000 mg BID

Hydrochlorothiazide 25 mg daily

Melatonin 3 mg QHS

Acetaminophen 1000 mg TID

Lorazepam 0.5 mg QHS

**Opioids:** 

None

Non-pharmacological strategies:

None



# **Opioid Therapy?**

### **Answer: No**

Reason: No evidence for benefit in fibromyalgia Instead of opioids, provider may want to consider opportunities to optimize non-opioid therapy (including non-pharmacological treatment options)



Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724

Busse, Jason, et al. "The 2017 Canadian guideline for opioids for chronic non-cancer pain." Hamilton, ON (2017).



# Preferred Non-Pharmacological Treatment for Fibromyalgia

- Patient has persistent pain and functional limitations
- Non-pharmacological approaches have not yet been trialled

A discussion of evidence-based non-pharmacological options should be considered.



# Non-Drug Treatments for Fibromyalgia

Cornerstone of treatment is non-pharmacological and psychosocial interventions (should be considered and offered in all patients).





# Non-Drug Treatments for Fibromyalgia

### **Exercise**

Exercise may lower pain for people with many types of chronic pain, such as low back pain, knee osteoarthritis, hip osteoarthritis, fibromyalgia, rheumatoid arthritis, and neck pain.<sup>1</sup>

Exercise: Aerobic (e.g., walking), strengthening, core stabilizing, therapeutic aquatic exercise; yoga; Tai Chi \*Graduated exercise program³

# Cognitive Behavioral Therapy (CBT)

CBT may lower pain for people with low back pain, neck pain, knee osteoarthritis, and fibromyalgia.<sup>2</sup>

Psychological: CBT, Mindfulness; Self-management programs<sup>3</sup>

<sup>1</sup>CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Physical Methods. Published online 2020.

<sup>2</sup>CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Psychological Methods. Published online 2020.

3Centre for Effective Practice (CEP). Providers | Chronic Non-Cancer Pain. https://cep.health/clinical-products/chronic-non-cancer-pain/



# Non-Drug Treatments for Fibromyalgia

### **Mindfulness**

Mindfulness may lower pain for people with low back pain and fibromyalgia<sup>1</sup>

**Hyperbaric Oxygen<sup>2</sup>** 

<sup>1</sup>CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Psychological Methods. Published online 2020.

<sup>2</sup>CADTH, Non-Opioid Options for Managing Adult Chronic Pain, Published online 2020.



# What about current non-opioid drug treatments?

- Patient reports persistent sleep problems due to pain, and dizziness that she attributes to her current medication
- It is important in Fibromyalgia patients to closely monitor and re-evaluate drug therapy, especially in older patients who are at increased risk of side effects

If patient is open to trialling non-pharmacological treatments and pain and other symptoms improve, consider whether re-evaluation of current drug therapies (i.e., dose reduction) is warranted



# **Monitoring**

Patient's treatment should be monitored closely (using validated scales) for benefits and side effects, particularly related to her functional status

### What if she doesn't see a benefit...

If non-pharmacological treatments trialled do not improve the patient's condition, consider trying an alternative non-pharmacological approach with evidence of benefit in fibromyalgia





### **Patient Resources**

Self-management approaches and formal non-pharmacological therapy can both play a role in the patient's overall care plan



https://cadth.ca/tools/non-drug-ways-manage-chronic-pain See: Resources for People Living With Chronic Pain



# **Access and Availability**

May need to consider limited availability of non-pharmacological treatments

Factors such as wait times (particularly for specialty care), lack of public funding, and issues regarding referrals and coordination/continuity of care may apply

#### CADTH

#### ENVIRONMENTAL SCAN

Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan

Service Line: Environmental Scan Issue: 81 Publication Date: November 2018 Report Length: 91 Pages

Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan. CADTH. 2018.



# **Addressing Access Issues**

- Consider referral to multidisciplinary practitioners and services, even if not available in a clinical or program setting
- Consider self-management approaches and other low-cost strategies with evidence for benefit in fibromyalgia



Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan. CADTH. 2018.



# Clinician Tool to Support Self-Management

#### Thinking Outside the Medicine Cabinet: CADTH Non-Drug Ways to Manage Chronic Pain CADTH completed a series of evidence reviews to appraise and summarize the research on the effectiveness of non-drug methods for the treatment of chronic, non-cancer pain. These reviews were used to develop a series of printable patient handouts and clinician evidence summaries, which can be found at cadth.ca/chronicpain. Clinician summaries include "practical considerations," which are useful tips and strategies for recommending the use of each non-drug method to patients. Evidence Bottom Line **Physical Methods** Manual Therapy Acupuncture Exercise may lower pain for people with Acupuncture may lower pain for people Manual therapy may lower pain for many types of chronic pain, such as with low back pain, hip osteoarthritis. people with chronic low back pain (spine low back pain, knee osteoarthritis, hip osteoarthritis, headache, shoulder pain. manipulation and massage), neck pain osteoarthritis, fibromyalgia, rheumatoid pelvic pain syndrome or prostatitis. (massage), and tension headaches arthritis, and neck pain\* sciatica, and myofascial pain.\* (spine manipulation).\* Psychological Methods Cognitive Behavioural Therapy (CBT) Mindfulness may lower pain for people CBT may lower pain for people Yoga may lower pain for people with low with low back pain and fibromyalgia.\* with low back pain, neck pain, knee back pain and primary dysmenorrhea.\* osteoarthritis, and fibromyalgia.\*







### **Patient Profile**

Age: 55 years Sex: Female



Traumatic back injury due to car accident



Surgery to address injury



Persistent pain 1 year after surgery.
Currently taking opioids as "nothing else works" and therefore hesitant to reduce or stop



### **Overview**




### **Medical Conditions**

- Previous spinal cord surgery after car accident
- Chronic pain for 1+ years
- Unmanaged anxiety and depression



### **Overview**




### **Functional Status**

- Lives alone
- Brief Pain Index (BPI) (70/90)
- Pain is 7/10 (VAS)



## **Overview**



### Dominant pain mechanism:

Nociceptive



## **Additional Information**

- Pain is constant but most severe in the morning
- Patient describes pain as intolerable
- Pain affecting relationships
- Limited ability to conduct activities of daily living
- Recent escalation of anxiety and depression
- Sleep is greatly affected



## **Current Therapy**

#### Non-opioid drug treatments:

- Clonazepam 1 mg QHS
- Past trials of morphine, NSAIDs, amitriptyline, and nabilone unsuccessful

#### **Opioids:**

- Past trials of morphine
- Oxycodone ER 40 mg BID

Non-pharmacological strategies:

None



## **Dominant Pain Mechanism**

#### Nociceptive Symptoms and Signs

- Pain localized to the area of injury or dysfunction (somatic referral)
- Intermittent and sharp pain with movement or mechanical provocation
- Constant dull ache or throbbing at rest
- Associated with dysesthesias (e.g., crawling sensation)

- Clear, proportionate relationship with aggravating/easing factors
- Absence of:
  - Night pain / disturbed sleep
  - Antalgic (i.e., pain relieving)
     postures / movement patterns
  - Pain described as burning, shooting, sharp or "electric shock like"

Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 3 of 3: symptoms and signs of nociceptive pain in patients with low back (± leg) pain. Man Ther. 2012;17(4):352-357. doi:10.1016/j.math.2012.03.002



## **Current Therapy**

#### Non-opioid drug treatments:

- Clonazepam 1 mg QHS
- Past trials of morphine, NSAIDs, amitriptyline, and nabilone unsuccessful

#### **Opioids:**

- Past trials of morphine
- Oxycodone ER 40 mg BID

Non-pharmacological strategies:

None



## **Optimizing Non-Opioid Drug Tx**

- Increased risk of side effects of respiratory depression and overdose with concurrent use of opioid and benzodiazepine
- Consider eventual tapering and discontinuation of clonazepam

Duloxetine (SNRI) is effective for pain control among people with low back pain; consider openness to trialling this medication


Qaseem, Amir, et al. "Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians." Annals of internal medicine 166.7 (2017): 514-530.



## **Optimizing Non-Opioid Drug Tx**

- Patient's depression and anxiety is poorly managed and may be contributing to poor pain control. Further assessment of depression and anxiety is warranted
- Patient reports persistent sleep deprivation

If open to a trial of Duloxetine it may also help to address patients' anxiety and depression



Qaseem, Amir, et al. "Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians." Annals of internal medicine 166.7 (2017): 514-530.



## **Non-Pharmaceutical Options**

Physical	Psychological	Preventive	Other
<sup>3</sup> ▲ Occupational therapy (using biopsychosocial approach)	<sup>2,3</sup> ▲ Yoga	<sup>3▲,5</sup> Body weight modifications	<sup>3</sup> ▲ Magnesium (Oral or IV)
<sup>1,3,4</sup> ▲ Manual Therapy	<sup>2,3</sup> ●,4Cognitive Behavioural Therapy (CBT)	<sup>3▲,5</sup> Customized or prefabricated shoe inserts	<sup>4</sup> Self Management Programs
<sup>3</sup> ▲ Physiotherapy	<sup>2,4</sup> Mindfulness		<sup>4</sup> TENS
1,3 ●,4Exercise  Types of exercise with evidence for benefit: <sup>4</sup> Strengthening exercise;  Core stabilizing exercise; Yoga;  Therapeutic aquatic exercise	<sup>4</sup> Acceptance and Commitment Therapy (ACT)		<sup>4</sup> Low-level laser therapy
<sup>1</sup> Acupuncture	<sup>4</sup> Respondent Therapy	3•Reasonable amount of evidence	
	<sup>4</sup> Behavioural Therapies	▲Some evidence to indicate effectiveness  1,2,4 Level of evidence varies, see primary source	

<sup>1</sup>CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Physical Methods. Published online 2020. <sup>2</sup>CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Psychological Methods. Published online 2020. <sup>3</sup>CADTH. Non-Opioid Options for Managing Adult Chronic Pain. Published online 2020. <sup>4</sup>Centre for Effective Practice (CEP) Providers | Chronic Non-Cancer Pain. <sup>5</sup>CADTH. Non-Pharmacological Methods for Managing Chronic Pain: Preventive Methods. Published online 2020.



## **Optimizing Non-Pharmaceutical Therapy**

- Patient is not currently utilizing any non-pharmacological strategies to complement care
- There is evidence for a benefit of physical and psychological non-pharmacological therapies in low back pain

Discuss whether the patient could incorporate some form of exercise and psychological support into their therapy



## **Opioid Therapy?**

## **Answer: May be opportunity to taper** and discontinue

**Reason:** Unclear benefit and therefore limited role for opioids in chronic low back pain and concern about potential harms

Based on patient's current status there may be an opportunity to optimize non-opioid drug therapy and non-pharmacological treatment options





## **Issues with Current Opioid Therapy**

- Opioid dose is above 90 mg morphine equivalent dose daily (risk of opioid use disorder, overdose)
- Limited benefit from opioid but resistant to change
- Recommendation to explore rotation and tapering, considering patient preferences in mgmt



## **Addressing Opioid Use**

Given lack of benefit from current opioid therapy and the risk of opioid use disorder and other harms, good opportunity to discuss reasons for resistance to change with patient. If appropriate recommend tapering and other treatment options.

There may be an opportunity to discuss harms and provide risk reduction (naloxone kit) and education



## **Tools for Tapering**

- Shared decision-making
- Interdisciplinary care
- SMART goals
- Consideration of harms
- Outlines general approach
- Withdrawal management
- Template for tapering plan and follow-up

#### **Talking points:**

"Chronic pain is a complex disease and opioids alone cannot adequately address all of your pain related needs"





Opioid Tapering Protocol www.deprescribingnetwork.ca/tapering



**Opioid Tapering Template** 



## **Motivational Approach**

- Elicit and listen carefully; consider linking together pros and cons (if any)
  - "Tell me about the upsides and downsides you see from your opioids"
- Provide individualized benefits and risks to review with patients
  - "It seems from the level of pain you are reporting that you are getting minimal relief from the opioids you are taking and there might be some potentially beneficial non-opioid alternatives that we haven't yet considered"
- Elicit
  - "How do you feel now knowing some of this information?"



## **Motivational Approach**

#### **Avoid**

"Righting Reflex" e.g., "We need to reduce your dose of opioids because the guidelines recommend it"





Chronic neuropathic pain secondary to illness



## **Patient Profile**


Age: 80 years Sex: Male



Impaired physical function and quality of life



Allodynia and heat hyperalgesia



Diagnosed with post-herpetic neuralgia and experiencing flank pain and headaches for approx. 6 months



Recent complaints of worsening stress and anxiety due to pain and itching



## **Overview**



#### **Medical conditions**

- Post-herpetic neuralgia
- Generalized anxiety disorder
- Type II diabetes (well controlled)

#### Select labs / vitals

- A1C 6.7%
- CrCl 70 mL/min



## **Overview**




#### **Functional status**

- Lives with spouse
- Pain is 8/10 (VAS)
- Patient reported quality of life is poor
- DN4 score of 6



## **Overview**



#### **Dominant pain mechanism:**


• Peripheral neuropathic



## **Douleur Neuropathique 4 (DN4)**

- Patient scored 6/10
- Neuropathic pain likely

Bouhassira, Didier, et al. "Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)." pain 114.1-2 (2005): 29-36





## **Dominant Pain Mechanism**

## (Peripheral) Neuropathic Symptoms and Signs

- Pain referred in a dermatomal or cutaneous distribution
- History of nerve injury, pathology, or mechanical compromise
- Pain/symptom provocation with mechanical/movement tests (e.g., active/passive, neurodynamic) that move/load/compress neural tissue

Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: part 2 of 3: symptoms and signs of peripheral neuropathic pain in patients with low back (± leg) pain. Man Ther. 2012;17(4):345-351. doi:10.1016/j.math.2012.03.003



## **Additional Information**

- Pain not responsive to NSAIDs or acetaminophen and is interested in alternative pharmacological treatment
- Partial response to other current non-opioid drug treatments; recent addition of amitriptyline to drug therapy has not improved symptoms
- Pain, particularly headaches, interfering with sleep
- Ability to engage in exercise and social life limited since onset of pain
- Symptoms daily, worse at night



## **Current Therapy**

#### Non-opioid drug treatments:

Amitriptyline 75 mg QHS (started 3 months ago)

Gabapentin 300 mg TID

Lidocaine patches (topical) (5%)

Metformin 1,000 mg BID

Sitagliptin 100 mg daily

#### **Opioids:**

None

Non-pharmacological strategies:

None



## **Opioid Therapy?**

#### **Answer: No**

**Reason**: Additional non-opioid drug treatments available and not yet trialled

Instead of opioids, provider may want to consider opportunities to optimize non-opioid therapy (including non-pharmacological treatment options)





## **Non-Opioid Options**

Psychological	Non-opioid drug Tx	Other
Acceptance and Commitment Therapy	Carbamazepine	Transcutaneous electrical nerve stimulation (TENS)
	Gabapentin	
	Pregabalin	
	Tricyclic antidepressants	
	Duloxetine	
	Topical and medical cannabinoids	

Treatments are suggested for neuropathic pain, not specifically post-herpetic neuralgia Level of evidence varies, see primary source

Centre for Effective Practice (CEP) Providers | Chronic Non-Cancer Pain.



## **Optimizing Non-Opioid Therapy**

Patient's stress and anxiety is poorly managed and may be contributing to poor pain control

Consider referral to psychological consult with recommendation for acceptance and commitment therapy (ACT) due to chronic symptoms

While patient is interested in other medications to manage pain, non-opioid and non-pharmacological approaches should be trialled before consideration of opioid therapy

Due to lack of effect of amitriptyline, consider switching amitriptyline to duloxetine, which may address some of the escalating anxiety and post-herpetic neuralgia symptoms




## In Summary

- CNCP affects many Canadians and is a major public health concern
- Not all pain is the same assessment of the dominant pain mechanism may support optimal tailored care
- Non-pharmacological and non-opioid strategies to treat chronic pain are recommended as first-line therapy
- Access to and availability to non-pharmacological treatments may be limited; however, there is good evidence to support various modalities for many types of pain
- Guidelines and tools, based on the best available evidence, are available to inform pain management, including the use of non-drug strategies, for providers and individuals living with CNCP


# For Key References and Resources of Potential Interest....


See the Supplemental Resource Library available with the course material





## **CADTH Pain Resources**






www.cadth.ca/pain

www.cadth.ca/opioids



### **Patient Resources**

**New Brunswick Service Directory** www.letstalkopioids.ca/patients/






## **Provider Resources**

Tools for Safe Practice
Service Directory
Information on the Opioid Crisis and
Alternative Tx options

www.letstalkopioids.ca/physicians/





## **Connect With Us**



@CADTH\_ACMTS



facebook.com/cadth.acmts



linkedin.com/company/cadth



requests@cadth.ca



## **Subscribe**

Sign up at <u>cadth.ca/subscribe</u> to get updates sent directly to your inbox.

#### **CADTH E-Alerts**

Calls for stakeholder feedback and patient group input, plus other time-sensitive announcements.

#### **New at CADTH**

Monthly newsletter including a summary of new reports plus corporate news, announcements of upcoming events, and more.

#### **CADTH Symposium and Events**

Updates about our flagship annual Symposium, workshops, webinars and other events.



## **Thank You**



# CADTH Evidence Driven. ACMTS Preuves à l'appui.